Understanding how IL-17 contributes to autoimmune diseases
Molecular Mechanisms of IL-17-dependent autoimmune signaling
This study is looking at how a specific protein involved in the immune system might help us understand and treat autoimmune diseases better, so patients can eventually benefit from new and improved therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10734061 on NIH RePORTER |
What this research studies
This research investigates the role of IL-17 and Th17 cells in driving autoimmune and inflammatory conditions. By exploring the molecular mechanisms behind IL-17 signaling, the study aims to identify new therapeutic targets and biomarkers that could lead to more effective treatments. The researchers have discovered a novel RNA binding protein that plays a crucial role in IL-17 signaling, and they will further investigate how this protein affects disease pathology. Patients may benefit from insights that could lead to improved therapies for various autoimmune diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from autoimmune diseases such as psoriasis, multiple sclerosis, or other inflammatory conditions.
Not a fit: Patients with non-autoimmune conditions or those not affected by IL-17 related pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for autoimmune diseases, improving patient outcomes.
How similar studies have performed: Previous research has shown success in targeting the IL-17 pathway for conditions like psoriasis, indicating potential for similar advancements in other autoimmune diseases.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Gaffen, Sarah L — University of Pittsburgh at Pittsburgh
- Study coordinator: Gaffen, Sarah L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.